GC entities lift Artiva stake in May 2026 offering

Artiva Biotherapeutics received an updated ownership disclosure from GC Corp, GC Cell Corporation and Yong‑Jun Huh following their participation in Artiva’s May 2026 underwritten offering.

Rhea-AI Filing Summary

Artiva Biotherapeutics received an updated ownership disclosure from GC Corp, GC Cell Corporation and Yong‑Jun Huh following their participation in Artiva’s May 2026 underwritten offering. GC Corp bought 1,085,069 shares and GC Cell Corporation bought 347,222 shares of common stock at $11.52 per share.

After these purchases, GC Corp is reported as beneficially owning 5,999,703 shares, or 12.3% of Artiva’s common stock, and GC Cell Corporation 1,607,734 shares, or 3.3%, based on 48,588,198 shares outstanding. Yong‑Jun Huh may be deemed a beneficial owner of the shares held by GC Corp and GC Cell for Section 13(d) purposes but expressly disclaims beneficial ownership for other purposes.

Insights

Equity ownership analyst

Large strategic holder boosts Artiva stake via May 2026 offering.

GC Corp and subsidiary GC Cell Corporation acquired 1,432,291 Artiva shares in the May 2026 underwritten offering at $11.52 per share, spending about $16.5M. This brings GC Corp’s reported beneficial stake to 5,999,703 shares, or 12.3% of the company.

GC Cell holds an additional 1,607,734 shares, or 3.3%. Control ultimately rests with GC Corp’s board, and Yong‑Jun Huh may be deemed a beneficial owner only for Section 13(d) reporting, which he expressly disclaims otherwise. The filing signals a sizeable, concentrated holder rather than a change in corporate control.

Key Figures

GC Corp purchase: 1,085,069 shares at $11.52/share GC Cell purchase: 347,222 shares at $11.52/share Aggregate purchase price: $16,499,992.32 +3 more

6 metrics

GC Corp purchase 1,085,069 shares at $11.52/share Bought in May 2026 underwritten offering

GC Cell purchase 347,222 shares at $11.52/share Bought in May 2026 underwritten offering

Aggregate purchase price $16,499,992.32 Total paid by GC Corp and GC Cell in May 2026 offering

GC Corp beneficial ownership 5,999,703 shares (12.3%) Artiva common stock after May 2026 offering

GC Cell beneficial ownership 1,607,734 shares (3.3%) Artiva common stock after May 2026 offering

Shares outstanding 48,588,198 shares Artiva common stock outstanding upon May 2026 offering closing

Key Terms

beneficial owner, Schedule 13D, underwritten offering, prospectus supplement, +1 more

5 terms

beneficial owner financial

"Mr. Yong-Jun Huh may be deemed beneficial owner, for purposes of Section 13(d) of the Act"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Schedule 13D regulatory

"originally filed with the Securities and Exchange Commission on July 29, 2024 (the "Statement") by the Reporting Persons"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

underwritten offering financial

"from the underwriters of the Issuer's underwritten offering (the "May 2026 Offering")"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

prospectus supplement regulatory

"described in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on May 8, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

joint filing agreement regulatory

"The agreement among the Reporting Persons to file this jointly in accordance with Rule 13d-1(k)... is attached hereto as Exhibit 99.1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Artiva Biotherapeutics (ARTV) shares did GC Corp buy in May 2026?

GC Corp bought 1,085,069 Artiva shares in May 2026 at $11.52 per share. The purchase was made from the underwriters in the company’s May 2026 underwritten offering, using GC Corp’s working capital as the funding source.

What total amount did GC Corp and GC Cell invest in Artiva Biotherapeutics (ARTV)?

GC Corp and GC Cell invested an aggregate $16,499,992.32 in Artiva common stock. This covered 1,085,069 shares for GC Corp and 347,222 shares for GC Cell at $11.52 per share in the May 2026 underwritten offering.

What percentage of Artiva Biotherapeutics (ARTV) does GC Corp now beneficially own?

GC Corp is reported as beneficially owning 5,999,703 Artiva common shares, representing 12.3% of the class. This percentage is calculated using 48,588,198 shares of common stock outstanding upon closing of the May 2026 offering.

What is GC Cell Corporation’s ownership stake in Artiva Biotherapeutics (ARTV)?

GC Cell Corporation beneficially owns 1,607,734 shares of Artiva common stock, equal to 3.3% of the outstanding class. These shares are held directly by GC Cell and are part of the broader ownership structure associated with GC Corp.

How many Artiva Biotherapeutics (ARTV) shares are outstanding after the May 2026 offering?

The ownership percentages in the filing are based on 48,588,198 Artiva common shares outstanding. This share count reflects the number of shares outstanding upon the closing of the company’s May 2026 underwritten offering, as described in its prospectus supplement.

How is Yong-Jun Huh related to GC Corp’s stake in Artiva Biotherapeutics (ARTV)?

Yong‑Jun Huh is GC Corp’s Chief Executive Officer and a board member, so he may be deemed a beneficial owner of Artiva shares held by GC Corp and GC Cell for Section 13(d) purposes, but he expressly disclaims beneficial ownership for any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 04:38 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

ARTIVA BIOTHERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04317A107

(CUSIP Number)

Yong-Jun Huh
107 Ihyeon-ro, 30beon-gil, Giheung-gu, Yongin-si
Gyeonggi-do, M5, 16924
82-31-260-9300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 04317A107

1

Name of reporting person

GC Corp

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

KOREA, REPUBLIC OF

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,999,703.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,999,703.00

11

Aggregate amount beneficially owned by each reporting person

5,999,703.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

12.3 %

14

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13D

CUSIP Number(s): 04317A107

1

Name of reporting person

GC Cell Corporation

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

KOREA, REPUBLIC OF

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,607,734.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,607,734.00

11

Aggregate amount beneficially owned by each reporting person

1,607,734.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.3 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP Number(s): 04317A107

1

Name of reporting person

Yong-Jun Huh

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

KOREA, REPUBLIC OF

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,999,703.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,999,703.00

11

Aggregate amount beneficially owned by each reporting person

5,999,703.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

12.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: ARTIVA BIOTHERAPEUTICS, INC.
(c)	Address of Issuer's Principal Executive Offices: 5505 Morehouse Drive, Suite 100, San Diego, CALIFORNIA , 92121.
Item 1 Comment: This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on July 29, 2024 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 2.	Identity and Background
(a)	This Schedule 13D is being filed on behalf of GC Corp., GC Cell Corporation and Yong-Jun Huh. GC Corp., GC Cell Corporation and Yong-Jun Huh are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act"), is attached hereto as Exhibit 99.1. The Reporting Persons' beneficial ownership of the Issuer's Common Stock consists of (i) 4,391,969 shares of Common Stock directly held by GC Corp. and (ii) 1,607,734 shares of Common Stock directly held by GC Cell Corporation. Mr. Yong-Jun Huh serves as Chief Executive Officer of GC Corp. and is a member of the board of directors of GC Corp. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. Mr. Yong-Jun Huh may be deemed beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by GC Corp. and GC Cell Corporation. Mr. Yong-Jun Huh disclaims beneficial ownership of the securities reported in this Schedule 13D other than for the purpose of determining his obligations under Section 13(d) of the Act, and the filing of this Schedule 13D shall not be deemed an admission that Mr. Yong-Jun Huh is the beneficial owner of such securities for any other purpose.
Item 3.	Source and Amount of Funds or Other Consideration
	On May 11, 2026, GC Corp purchased 1,085,069 shares of Common Stock at a price of $11.52 per share from the underwriters of the Issuer's underwritten offering (the "May 2026 Offering") and GC Cell Corporation purchased 347,222 shares of Common Stock at a price of $11.52 per share in the May 2026 Offering. The aggregate purchase price for all securities acquired by GC Corp and GC Cell Corporation in the May 2026 Offering was $16,499,992.32, which was funded by the working capital of GC Corp.
Item 5.	Interest in Securities of the Issuer
(a)	The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D/A is incorporated by reference. The percentage set forth in row 13 is based on 48,588,198 shares of Common Stock outstanding upon the closing of the May 2026 Offering described in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on May 8, 2026.
(b)	The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D/A and Item 2 above is incorporated by reference.
(c)	Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
(d)	No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D/A.
(e)	Not applicable
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13D filed with the SEC on July 29, 2024).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GC Corp

Signature:	/s/ Yong-Jun Huh
Name/Title:	Yong-Jun Huh, Chief Executive Officer
Date:	05/28/2026

GC Cell Corporation

Signature:	/s/ Jaiwang Kim
Name/Title:	Jaiwang Kim, Chief Executive Officer
Date:	05/28/2026

Yong-Jun Huh

Signature:	/s/ Yong-Jun Huh
Name/Title:	Yong-Jun Huh
Date:	05/28/2026